阿德福韦治疗HBV基因变异的临床观察研究  

Analysis of HBV mutation resistant to adefovir dipivoxil

作　　者：曹莉萍[1] 叶倩[1] 陈光明 谭立明[1] 刘川[1] 李军[1] 

机构地区：[1]南昌大学第二附属医院检验科,江西南昌330006 [2]高安市瑞州医院,江西高安330800

出　　处：《实验与检验医学》2011年第5期477-478,485,共3页Experimental and Laboratory Medicine

基　　金：江西省卫生厅资助项目(NO.20073091)

摘　　要：目的了解接受阿德福韦治疗后HBV的基因变异情况。方法收集我院2007年1月至2009年1月门诊接受阿德福韦治疗的慢性乙肝患者100例,对其进行为期2年的随访,于治疗的不同阶段采用巢式聚合酶链反应—限制性片段长度多态(ntPCR-RFLP)技术对HBV病毒基因变异(rtN236T变异和rtA181V变异)进行检测,了解HBV基因突变情况。结果 6个月检测无变异基因;12个月检测出变异基因病例3例;18个月检测出变异基因病例5例;24个月检测出变异基因病例6例。结论阿德福韦治疗对HBV可产生一定的基因变异,与用药疗程有一定相关性。Objective To evaluate HBV mutation of the cases received adefovir dipivoxil.Methods rtN236T and rtA181V mutations of chronic hepatitis B were detected in different treatment stages by nest PCR-RFLP assay.Results None with rtN236T and rtA181V mutations were found in 6 months after treatment.3,5 and 6 cases of rtN236T and rtA181V mutations were found after 6,12 and 24 months respectively.Conclusions HBV mutation can be detected in chronic hepatitis B patients received adefovir dipivoxil,and it is related to the treatment course.

关 键 词：阿德福韦 乙型肝炎病毒 变异 

分 类 号：R512.62[医药卫生—内科学] Q343.13[医药卫生—临床医学]